CARL ZEISS MEDITEC AG Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, is satisfied with the start to the year: 'We closed the first quarter with encouraging increases in revenue and operating profit. And we continue to consistently pursue our strategy of being a solutions provider for our customers worldwide.'
Strongest growth in Ophthalmic Devices SBU
Ophthalmology, in particular, contributed to growth: the Ophthalmic Devices strategic business unit (SBU) increased its revenue by 8.5 percent in the first quarter of the current fiscal year (adjusted for currency effects: 7.4 percent), to €207.6m, compared with €191.3m in the same period of the previous year. The business with laser systems for refractive correction developed particularly well. Additional growth is anticipated during the further course of the fiscal year due to the planned launch of the minimally invasive laser surgery ReLEx® SMILE in the USA. The sub-segment of Surgical Ophthalmology, the business with intraocular lenses and devices for the treatment of cataracts, also performed well. In Diagnostics, on the other hand, competitive pressure remained strong. The EBIT margin of the Ophthalmic Devices SBU increased further. One-time capital gains of €7.7m from the disposal of assets at a Surgical Ophthalmology site in Ontario, California, contributed to this growth.
Revenue in the Microsurgery SBU grew by 1.6 percent (adjusted for currency effects: 0.2 percent). Revenue from surgical microscopes and visualization solutions climbed to €72.4m, compared with €71.3m in the prior year. The key markets in North America and Asia exhibited a sideways trend at the start of the year. The profitability of the Microsurgery SBU remained at an above-average level and increased slightly compared with the prior year.
APAC becomes largest reporting region
Another strong performance was achieved by the Asia/Pacific (APAC) region. At €105.8m, revenue was significantly higher than the prior-year figure of €83.6m - an increase of 26.6 percent (adjusted for currency effects: 22.9 percent). A large part of this growth is attributable to the Chinese market, as well as Southeast Asia and India.
Revenue in the EMEA region declined by 7.2 percent (adjusted for currency effects: -6.6 percent), to €83.7m (prior year: €90.2m). There was a downturn in business particularly in the United Kingdom, Southern Europe and the Middle East.
Revenue in the Americas region was largely stable, increasing by 1.9 percent (adjusted for currency effects: 0.7 percent) to revenue of €90.5m (prior year: €88.8m).
Earnings per share (EPS) increased significantly year-on-year, to €0.38 (prior year: €0.21). The increase in operating profit contributed to this - the prior year was also still affected significantly by extraordinary expenses arising from impairments on an at-equity holding and by negative results from currency hedges.
Carl Zeiss Meditec AG's objective remains to continue growing at least at the same rate as the underlying market in fiscal year 2016/17. The EBIT margin is expected to be within the range also forecast for the medium term, of 13 percent to 15 percent.
Revenue by strategic business unit
|
Figures in €m |
3 Months 2016/17 |
3 Months 2015/16 | Change compared to prior year | Change compared to prior year* |
|---|---|---|---|---|
| Ophthalmic Devices | 207.6 | 191.3 | +8.5% | +7.4% |
| Microsurgery | 72.4 | 71.3 | +1.6% | +0.2% |
| Total | 280.0 | 262.6 | +6.6% | +5.4% |
* adjusted for currency effects
Revenue by region
|
Figures in €m |
3 Months 2016/17 |
3 Months 2015/16 | Change compared to prior year | Change compared to prior year* |
|---|---|---|---|---|
| EMEA | 83.7 | 90.2 | -7.2% | -6.6% |
| Americas | 90.5 | 88.8 | +1.9% | +0.7% |
| APAC | 105.8 | 83.6 | +26.6% | +22.9% |
| Total | 280.0 | 262.6 | +6.6% | +5.4% |
* adjusted for currency effects
Press Contacts:
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Fax:
investors.meditec@zeiss.com
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 2,900 employees worldwide, the Group generated revenue of € 1,088 million in financial year 2015/16 (to 30 September).
The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percentof its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries.
For more information visit our website at:
www.zeiss.com/med
Number: 0011-2017-ENG OP
Number of Words: 909
Number of Characters: 7148
Carl Zeiss Meditec AG published this content on 10 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 February 2017 08:13:04 UTC.
Original documenthttp://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/4D3D1BACEFAEDDE9C12580C200238AA8?OpenDocument
Public permalinkhttp://www.publicnow.com/view/AA09AD45757681405C0B723400D3F70DC01CF816
